T-Cell Immunotherapy Market, 2030 - Competitive Landscape Features a Mix of Established Players and Start-ups, with Academic Institutes Spearheading Early-stage Development Activities

Dublin, June 08, 2018 (GLOBE NEWSWIRE) -- The "T-Cell Immunotherapy Market (3rd Edition), 2018-2030" report has been added to ResearchAndMarkets.com's offering.

The "T-Cell Immunotherapy Market, 2018-2030 (3rd edition)" report features an extensive study of the current market landscape and the future potential of T-cell immunotherapies (focusing particularly on CAR-T therapies, TCR therapies and TIL therapies). One of the key objectives of the study was to review and quantify the future opportunities associated with the ongoing development programs of both small and big pharmaceutical firms.

Cancer is known to be one of the leading causes of death worldwide, accounting for 0.6 million deaths in 2017 in the US alone. The World Health Organization states that the number of new cancer cases globally is expected to rise by 70% in the coming 20 years. Although cancer therapeutics continue to be one of the most active areas in terms of drug development, there is still a significant unmet need in this domain. Conventional cancer treatments, such as chemotherapy, surgery and radiation therapy, have demonstrated very limited efficacy in late-stage cancers. Specifically, chemotherapy and radiation therapy are also associated with several side effects. Their non-specific nature has severe detrimental effects on the patients' quality of life.

Amidst the current initiatives to develop more targeted anti-cancer therapies, immunotherapy has emerged as a highly potent option to eradicate tumor cells with minimal side effects. It is based on the principle of harnessing the innate potential of the immune system to target and destroy diseased cells. It encompasses several treatment approaches, such as monoclonal antibodies, immune checkpoint inhibitors, therapeutic vaccines, cytokine therapies and cell-based therapies. In recent years, adoptive T-cell therapy (ACT) has emerged as a potent and viable therapeutic intervention. There are certain key characteristics that render T-cells suitable for use as effective therapeutic tools; these include target specificity, adaptability and the capability to retain immunologic memory.

Close to 120 academic and research institutes across the globe have made significant contributions to this field, mostly by convening the initial research on potential product candidates. These efforts have built the intellectual framework for the establishment of several start-ups; in fact, during the last five years, over USD 8 billion has been invested by VC firms/other strategic investors. It is also worth highlighting that there have been more than 200 instances of collaborations between industry/academic stakeholders. The ongoing innovation has also led to the discovery of several novel molecular targets, strengthening the research pipelines of various companies engaged in this domain. Encouraged by the recent approval of two CAR-T therapies, namely Kymriah (Novartis) and Yescarta (Gilead Sciences), and a robust development pipeline, the T-cell immunotherapy market offers considerable promise to a number of industry stakeholders.

Key Topics Covered:

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Pillars of Cancer Therapy
3.3. Immunotherapy, an Emerging Therapeutic Option
3.4. Fundamentals of Cancer Immunotherapy
3.5. Classification of Cancer Immunotherapies
3.6. Historical Evolution of T-Cell Immunotherapies
3.7. Key Considerations of T-Cell Immunotherapies
3.8. Strategies Employed for Redirection of T-Cells
3.9. Manufacturing of Engineered T-Cells
3.10. T-Cell Transduction/Transfection Methods
3.11. Therapeutic Areas Targeted by T-Cell Immunotherapies
3.12. Key Challenges of T-Cell Immunotherapies

4. EMERGING TRENDS ON SOCIAL MEDIA
4.1. Chapter Overview
4.2. Trends on Twitter

5. MARKET LANDSCAPE
5.1. Chapter Overview
5.2. T-Cell Immunotherapies: A Promising Pipeline

6. KEY INSIGHTS
6.1. Chapter Overview
6.2. T-Cell Immunotherapies: Analysis by Popularity of Target Antigens
6.3. T-Cell Immunotherapies: CAR-T Clinical Trial Trends, Pre-2012-2018
6.4. T-Cell Immunotherapies: Clinical Trial Overview

7. CHIMERIC ANTIGEN RECEPTOR-T CELL THERAPY
7.1. Introduction
7.2. History of Development
7.3. Key Opinion Leaders
7.4. Anatomical Layout of Chimeric Antigen Receptor
7.5. CAR-T Construction Analysis
7.6. Development of Chimeric Antigen Receptors
7.7. Development of CAR-T Cells
7.8. Universal CAR-Ts
7.9. Route of Administration
7.10. Toxicity Concerns
7.11. Management of Toxicity Issues
7.12. CD19: An Attractive Target
7.13. Other Targets
7.14. Challenges Associated with CAR-T Therapies
7.15. Kymriah/Tisagenlecleucel/CTL019 (Novartis)
7.16. Yescarta/Axicabtagene Ciloleucel/KTE-C19 (Kite Pharma)
7.17. JCAR (Juno Therapeutics)
7.18. CAR-T Series (Cellular Biomedicine Group)
7.19. CD19 CAR (Takara Bio)
7.20. Dual Targeting CAR-T Cell Therapies (Autolus)
7.21. CAR-T Therapies (Sinobioway Cell Therapy/The First Affiliated Hospital of Anhui Medical University)

8. T-CELL RECEPTOR (TCR) BASED THERAPIES
8.1. Chapter Overview
8.2. Structure of the T-Cell Receptor
8.3. Differences Between CAR and TCR
8.4. History of Development
8.5. Mechanism of Action
8.6. Key Opinion Leaders
8.7. Safety Concerns
8.8. Prerequisites for Antigen-Specific T-Cell Receptors
8.9. Strategies to Enhance Antitumor Efficacy
8.10. SPEAR T-Cells (Adaptimmune)
8.11. ALT-801 (Altor BioScience)
8.12. IMCgp100 (Immunocore)
8.13. JTCR016 (Juno Therapeutics)
8.14. CMD-602/WT1 TCR Therapy (Cell Medica)
8.15. TBI-1301 (Takara Bio)

9. TUMOR INFILTRATING LYMPHOCYTES (TIL) BASED THERAPIES
9.1. Chapter Overview
9.2. History of Development
9.3. Key Opinion Leaders
9.4. Strategies to Enhance Efficacy
9.5. Prognostic Applications
9.6. Manufacturing Process
9.7. Autologous TIL Therapies (Iovance Biotherapeutics)
9.8. TIL (Nantes University Hospital)
9.9. TIL (Netherlands Cancer Institute)

10. KEY THERAPEUTIC AREAS FOR T-CELL THERAPIES
10.1. Chapter Overview
10.2. Hematological Malignancies
10.3. Solid Tumors

11. EMERGING TECHNOLOGIES
11.1. Chapter Overview
11.2. Genome Editing Technologies
11.3. Designing T-Cell Therapies with Improved Characteristics

12. PARTNERSHIPS AND COLLABORATIONS
12.1. Chapter Overview
12.2. Types of Partnership Models
12.3. T-Cell Immunotherapy Market: Partnerships and Collaborations

13. FUNDING AND INVESTMENT ANALYSIS
13.1. Chapter Overview
13.2. Types of Funding
13.3. T-Cell Immunotherapy Market: Funding and Investment Analysis

14. OTHER T-CELL IMMUNOTHERAPIES
14.1. Chapter Overview
14.2. Other T-Cell Immunotherapies
14.3. Treg Cell Therapy
14.4. T-Cell-based Vaccines
14.5. Virus-Driven T-Cell Therapies
14.6. Fucosylation Technology Platform
14.7. PD-1 Knockout Engineered T-Cell Therapy
14.8. TAC-T Cell Therapy
14.9. Gama Delta T-Cell Immunotherapy

15. CASE STUDY: CELL THERAPY MANUFACTURING
15.1. Chapter Overview
15.2. Introduction
15.3. Key Challenges
15.4. Current Trends
15.5. Key Considerations for a Manufacturing Site
15.6. Regulatory Landscape

16. T-CELL IMMUNOTHERAPY: COST PRICE ANALYSIS
16.1. Chapter Overview
16.2. Factors Contributing Towards High Price Tags of Cell/Gene Therapies
16.3. Pricing Models for T-Cell Immunotherapies
16.4. Reimbursement Considerations for T-Cell Immunotherapies

17. MARKET SIZING AND OPPORTUNITY ANALYSIS
17.1. Chapter Overview
17.2. Scope and Limitations
17.3. Forecast Methodology
17.4. Overall T-Cell Immunotherapy Market, 2018-2030
17.5. T-Cell Immunotherapy Market: Product-Wise Sales Forecasts

18. PROMOTIONAL ANALYSIS
18.1. Chapter Overview
18.2. Channels Used for Promotional Campaigns
18.3. Summary of Product Website Analysis
18.4. Summary of Patient Support Services and Informative Downloads
18.5. Kymriah: Promotional Analysis
18.6. Yescarta: Promotional Analysis

19. COMPANY PROFILES
19.1. Chapter Overview
19.2. Adaptimmune Therapeutics
19.3. Autolus
19.4. bluebird bio
19.5. CARsgen Therapeutics
19.6. Celgene
19.7. Cell Medica
19.8. Cellectis
19.9. Cellular Biomedicine Group
19.10. Immunocore
19.11. Innovative Cellular Therapeutics
19.12. Iovance Biotherapeutics
19.13. Kite Pharma (A Gilead Sciences Company)
19.14. Lion TCR
19.15. Novartis
19.16. Sinobioway Cell Therapy
19.17. Takara Bio
19.18. Unum Therapeutics
19.19. ZIOPHARM Oncology

20. CONCLUSION
20.1. With Steady Growth in the Development Pipeline, T-Cell based Therapies have Emerged as a Promising Segment of the Immunotherapy Market
20.2. Hematological Malignancies and Solid Tumors are Currently the Major Target Indications
20.3. The Competitive Landscape Features a Mix of Established Players and Start-ups, with Academic Institutes Spearheading Early-stage Development Activities
20.4. A Number of Novel Technology Platforms have also Emerged as Vital Enablers of Growth in this Market
20.5. Multiple Novel Types of Immunotherapies, other than CAR-T, TCR and TIL, are also Expected to Enter the Market in the Mid-Long Term
20.6. Increasing Partnership Activity and Financial Support from Various Investors are Indicative of the Lucrative Future Potential
20.7. The Premium Pricing of these Therapies Necessitate Appropriate Reimbursement and Promotional Strategies to Guarantee Commercial Success
20.8. Driven by the Approval of Two CAR-T Therapies and Encouraging Results of Late-stage Candidates, the Market is Expected to Grow Significantly in the Long Term

21. EXECUTIVE INSIGHTS
21.1. Chapter Overview
21.2. Cell Therapies
21.3. Celyad
21.4. Changhai Hospital
21.5. Iovance Biotherapeutics
21.6. Kite Pharma
21.7. Lion TCR
21.8. Theravectys
21.9. TxCell
21.10. University of Colorado
21.11. Waisman Biomanufacturing

22. APPENDIX 1: TABULATED DATA

23. APPENDIX 2: LIST OF COMPANIES

Companies Mentioned

• A*STAR's Genome Institute of Singapore
• Abramson Cancer Center
• AbVitro
• Acerta Pharma
• Acer Therapeutics
• Adaptimmune Therapeutics
• Adicet Bio
• Adimab
• Advanced BioScience Laboratories
• Advent Bioservices
• Adverum Biotechnologies
• Aeon Therapeutics (Shanghai)
• AFG Private Equity
• Affiliated Hospital to Academy of Military Medical Sciences
• AgenTus Therapeutics
• Agreen Biotech
• AGF Private Equity
• AJU IB Investment
• Aokai Biotech
• Akron Biotech
• Alaska Permanent Fund
• Albert Einstein College of Medicine
• Alexandria Venture Investments
• Allergan
• Alta Partners
• Alpine Immune Sciences
• Altor BioScience
• Amsterdam BioTherapeutics Unit
• Amgen
• Anhui Kedgene Biotechnology
• Anhui Provincial Hospital
• Antagene
• Anterogen
• apceth Biopharma
• Aquilo Capital Management
• ARBELE
• ARCH Venture Partners
• Argos Therapeutics
• ARIAD Pharmaceuticals
• Arix Bioscience
• Astellas Pharma
• AstraZeneca
• Asymptote
• Atara Biotherapeutics
• AT Impf
• Atlantic Bio GMP
• Atlas Venture
• Atreca
• Aurora Biopharma
• Autolus
• Avacta
• AVG Ventures
• BankInvest Biomedical Venture
• Batavia Biosciences
• Bavarian Nordic
• Baxalta
• Bayer
• Baylor College of Medicine
• Beijing Biohealthcare Biotechnology
• Beijing Doing Biomedical
• Beijing Genomics Institute
• Beijing Immunochina Medical Science and Technology
• Beijing Sanwater Biological Technology
• Beijing You'an Hospital
• Bellicum Pharmaceuticals
• Beth Israel Deaconess Medical Center
• Bezos Expeditions
• Bill & Melinda Gates Foundation
• BioAtla
• Bio Elpida
• Biogen
• BioLife Solutions
• Biomedical Catalyst
• BioNTech Innovative Manufacturing Services
• bluebird bio
• Boehringer Ingelheim
• Brace Pharma Capital
• Brammer Bio
• Broadfin Capital
• Broad Institute
• Bristol-Myers Squibb
• Cabaret Biotech
• Caladrius Biosciences
• California Institute for Regenerative Medicine
• Cancer Research UK
• Cancer Prevention Research Institute of Texas
• Captain T Cell
• Cardiff University
• Cartherics
• Caribou Biosciences
• Carina Biotech
• CARsgen Therapeutics
• Casdin Capital
• Casebia Therapeutics
• Cell Biotech
• Celdara Medical
• Cellectis
• Cell Design Labs
• Celgene
• Cell and Gene Therapy Catapult
• Cellenkos
• Cell Medica
• Cellular Biomedicine Group
• CELLforCURE
• Cell Therapies
• Cellular Therapeutics
• Celyad
• Center for Cell and Gene Therapy
• Center for Cell Manufacturing Ireland, NUI Galway
• Center for Research in Transplantation and Immunology
• Changhai Hospital
• CHDI Foundation
• Chengdu MedGenCell
• Chiesi Farmaceutici
• Children's Hospital of Philadelphia
• Children's Mercy Hospital
• Children's Oncology Group
• Children's Research Institute
• Chinese Academy of Sciences
• Chinese PLA General Hospital
• Christie NHS Foundation Trust
• Clough Capital Partners
• City of Hope National Medical Center
• Cognate BioServices
• Columbia University
• Cook MyoSite
• Copenhagen University Hospital
• Cormorant Asset Management
• Cowen Private Investments
• CRISPR Therapeutics
• Cryoport
• CureVac
• Cystic Fibrosis Foundation Therapeutics
• CytoLumina Technologies
• Cytovance Biologics
• Daiichi Sankyo
• Dana-Farber Cancer Institute
• Dangdai International Group
• Dartmouth College
• Deerfield Management
• Delenex Therapeutics
• Dendreon
• dievini Hopp Biotech
• Dongguan People's Hospital
• Dow AgroSciences
• DS Asset Management
• Duke Cancer Institute
• Easton Capital Investment Group
• EcoR1 Capital
• Editas Medicine
• Eli Lilly
• Edmond de Rothschild Investment Partners
• Endocyte
• ERS Genomics
• Eutilex
• Eureka Therapeutics
• F1 BioVentures
• F1 Oncology
• F2 Ventures
• Fate Therapeutics
• FetoLumina Technologies
• FGP Capital
• Financire IDAT
• Finnish Funding Agency for Technology and Innovation
• First Affiliated Hospital of Chengdu Medical College
• First Affiliated Hospital of Harbin Medical University
• First Affiliated Hospital of Sun Yat-sen University
• First Affiliated Hospital of Wenzhou Medical University
• First Affiliated Hospital of Zhejiang University
• First People's Hospital of Foshan
• F-Prime Capital
• Five Prime Therapeutics
• Flagship Pioneering
• Forbion Capital Partners
• Fondazione Telethon and Ospedale San Raffaele
• Foresite Capital
• Forevertek Biotechnology
• Formula Pharmaceuticals
• Fosun Pharmaceutical
• Fortress Biotech
• Franklin Templeton Investments
• Fred Hutchinson Cancer Research Center
• Fraunhofer Institute for Cell Therapy and Immunology
• Friedreich's Ataxia Research Alliance
• Fuda Cancer Hospital
• Fudan University
• Fujian Medical University
• GammaCell Bio-Technologies
• GammaDelta Therapeutics
• Gadeta
• Gene and Cell Therapy Lab
• GE Healthcare Life Sciences
• Ghent University Hospital
• GigaGen
• Gilead Sciences
• GlaxoSmithKline
• G.N. Tech Venture Capital
• Google Ventures
• Green Cross Cell
• Guangzhou Eighth People's Hospital
• Guangzhou First People's Hospital
• Guangzhou Xiangxue Pharmaceutical
• Guangzhou YiYang Biological Technology
• Guangdong Zhaotai InVivo Biomedicine
• Guy's and St Thomas' NHS Foundation Trust
• Hadassah Medical Center
• Hangzhou Cancer Hospital
• Harbin Medical University
• Harvard University
• Hebei Senlang Biotechnology
• Henan Cancer Hospital
• HengRui YuanZheng Bio-Technology
• Herlev Hospital
• Hitachi Chemical Advanced Therapeutics Solutions
• H. Lee Moffitt Cancer Center and Research Institute
• Howard Hughes Medical Institute
• Human Stem Cells Institute
• Hunan Zhaotai Yongren Medical Innovation
• iCarTAB BioMed
• iCell Gene Therapeutics
• Immatics Biotechnologies
• Immunocore
• Immune Therapeutics
• Immunovative Therapies
• Imperial College London
• Imperial Innovations Group
• Innovate UK
• Innovative Cellular Therapeutics
• Innovative Genomins Institute
• Intellia Therapeutics
• Intrexon
• Institut Curie
• Institut Pasteur
• Boston Children's Hospital
• Instituto de Salud Carlos III
• Invesco Perpetual
• Iovance Biotherapeutics
• Iowa State University Research Foundation
• Janus Capital Management
• Janssen Biotech
• Japan Science and Technology Agency
• Jazz Pharmaceuticals
• JCR Pharmaceuticals
• Jennison Associates
• Jiangsu Cancer Hospital
• JIC GenesisFountain Healthcare Ventures
• John Goldman Centre for Cellular Therapy
• Johns Hopkins University
• Jolly Innovation Ventures
• Jonsson Comprehensive Cancer Center
• Juno Therapeutics
• JW Biotechnology
• Kaitai Capital
• Karolinska University Hospital
• KBI Biopharma
• Keio University
• Khosla Ventures
• King's College London
• Kite Pharma
• Kolon Investment
• KTB Ventures
• Legend Capital
• Leiden University Medical Center
• Leucid Bio
• Lexicon Pharmaceuticals
• Life Technologies
• Lifeline Ventures
• Lilly Asia Ventures
• Lion TCR
• Living Pharmaceticals
• Lonza
• Loyola University
• Lbeck Institute of Experimental Dermatology
• MabQuest
• Malin
• Marino Biotechnology
• MaSTherCell
• Massachusetts General Hospital Cancer Center
• Matrix Capital Management
• MaxCyte
• Max Delbrck Center for Molecular Medicine in the Helmholtz Association
• MD Anderson Cancer Center
• Medarex
• Medical College of Wisconsin
• Medicxi Ventures
• Medigene
• MEDINET
• MedImmune
• Medpost Urgent Care
• Memorial Sloan Kettering Cancer Center
• Merck
• Merck Serono
• Merlin Nexus
• Mie University
• Millennium Pharmaceuticals
• Miltenyi Biotec
• MingJu Therapeutics (Shanghai)
• Molecular and Cellular Therapeutics
• MolMed
• MPM Capital
• Mustang Bio
• Nanjing Children's Hospital
• Nanjing Legend Biotech
• Nantes University Hospital
• NantKwest
• National Cancer Institute
• National Heart, Lung, and Blood Institute
• National Institute of Allergy and Infectious Diseases
• National Institutes of Health
• National University of Singapore
• Navy General Hospital (Beijing)
• NCL Innovation
• Nextech Invest
• New Enterprise Associates
• New Leaf Venture Partners
• New River Management
• NewVa Capital Partners
• New York Medical College
• Ningbo Cancer Hospital
• Nikon CeLL innovation
• Nipro
• Noile-Immune Biotech
• Novartis
• Novo Ventures
• Oaktree Capital Management
• ODYSSEE Venture
• Omega Funds
• Oncodesign
• OncoTracker
• OnCyte
• Ono Pharmaceutical
• Onyx Pharmaceuticals
• Opexa Therapeutics
• Opus Bio
• OrbiMed HealthCare Fund Management
• Ospedale Pediatrico Bambino Ges
• Oxford BioMedica
• Oxford MEStar
• Partners Innovation Fund
• Peking University
• Perceptive Advisors
• Peter MacCallum Cancer Centre
• Perceptive Advisors
• PersonGen BioTherapeutics (Suzhou)
• Pfizer
• PharmaCell
• Pharmicell
• Pinze Lifetechnology
• Polaris Partners
• PolyBioCept
• Pontifax
• Poseida Therapeutics
• Praxis Pharmaceutical
• Precision BioSciences
• Precision Genome Engineering
• Princess Margaret Cancer Centre
• Progenitor Cell Therapy
• ProMab Biotechnologies
• Puma Biotechnology
• Quogue Capital
• RA Capital Management
• Ramius Capital Group
• Rayne Cell Therapy Suite
• RedoxTherapeis
• Redmile Group
• Relieve Genetics
• Regeneron Pharmaceuticals
• Remeditex Ventures
• Renji Hospital
• Renmin Hospital of Wuhan University
• Ridgeback Capital Management
• Roche
• Rockland Immunochemicals
• Roger Williams Medical Center
• RoslinCT
• Royal Adelaide Hospital Cancer Centre
• Roswell Park Comprehensive Cancer Center
• RXi Pharmaceuticals
• Sabby Management
• Sangamo Therapeutics
• Sanofi-Genzyme BioVentures
• San Raffaele Hospital
• Scottish National Blood Transfusion Service
• Scottish Investment Bank
• Seattle Genetics
• Seattle Children's Hospital
• Second Affiliated Hospital of Guangzhou Medical University
• Sectoral Asset Management
• Second Military Medical University
• Second Xiangya Hospital of Central South University
• Servier
• Shanghai Bioray Laboratory
• Shanghai Changzheng Hospital
• Shanghai Cell Therapy Engineering Technology Research Center
• Shanghai Chest Hospital
• Shanghai Children's Medical Center
• Shanghai GeneChem
• Shanghai General Hospital
• Shanghai Houchao Biotechnology
• Shanghai Jiao Tong University School of Medicine
• Shanghai Longyao Biotechnology
• Shanghai Sunway Biotech
• Shanghai Tongji Hospital
• Shanghai Unicar-Therapy Bio-medicine Technology
• Sheba Medical Center
• ShengJing360.com
• Shenzhen BinDeBio
• Shenzhen Geno-immune Medical Institute
• Shenzhen Hornetcorn Biotechnology
• Shenzhen Institute for Innovation and Translational Medicine
• Shenzhen Second People's Hospital
• Shenzhen Sibiono GeneTech
• Shire International
• Sidney Kimmel Comprehensive Cancer Center
• Sigma-Aldrich
• Shionogi
• Sichuan University
• Sinobioway Cell Therapy
• Sinobioway Group
• SNU Bio Angel
• Southwest General Health Center
• Sorrento Therapeutics
• Spark Therapeutics
• Square 1 Bank
• Stage Cell Therapeutics
• Stanford University
• St. George's Hospital
• St. Jude Children's Research Hospital
• SOTIO
• StrideBio
• SR One
• SunTerra Capital
• Sun Yat-sen University
• Syncona
• SyndicateRoom
• Tactiva Therapeutics
• Takeda Pharmaceutical
• Takara Bio
• Targazyme
• Target ALS Foundation
• TC BioPharm
• T-Cell Factory
• TCR2 Therapeutics
• Tel Aviv Sourasky Medical Center
• TeneoBio
• Tesaro
• Tessa Therapeutics
• Tethys Health Ventures
• Terumo Medical
• Nanjing Drum Tower Hospital
• Beijing Pregene Science and Technology Company
• The First Affiliated Hospital of Guangdong Pharmaceutical University
• The First Affiliated Hospital of Guangzhou Medical University
• The First Affiliated Hospital of Soochow University
• The First People's Hospital of Yunnan
• The First People's Hospital of Lianyungang
• Thiel Capital
• Netherlands Cancer Institute
• The Ohio State University Comprehensive Cancer Center
• The Pregene (ShenZhen) Biotechnology Company
• Theravectys
• Henan University of Traditional Chinese Medicine
• Texas Emerging Technology Fund
• Thermo Fisher Scientific
• The Wistar Institute
• Third Military Medical University
• Third Rock Ventures
• Third Security
• Three Arch Opportunity Fund
• TILT Biotherapeutics
• Tianjin Medical University Cancer Institute and Hospital
• TiGenix
• TissueGene-C
• Tmunity Therapeutics
• TNK Therapeutics
• Tongji University School of Medicine
• Touchstone Innovations
• TRACT Therapeutics
• TrakCel
• Transgene
• Transposagen Biopharmaceuticals
• Triumvira Immunologics
• T. Rowe Price Associates
• TVAX Biomedical
• TVM Capital
• Two Blades Foundation
• Txcell
• UNC Lineberger Comprehensive Cancer Center
• Union Stem Cell & Gene Engineering
• Universal Cells
• University College London
• University Health Network, Toronto
• University of Birmingham
• University of British Columbia
• University of California
• University of Florida
• University of Lausanne
• University Medical Center Utrecht
• University of Milano-Bicocca
• University of Minnesota
• University of Pennsylvania
• University of Sydney
• University of Texas
• University of Zurich
• Uppsala University
• Unum Therapeutics
• Utrecht Holdings
• Vaccinogen
• Valeant Pharmaceuticals
• Vecura
• Venrock
• Versant Ventures
• Vertex Pharmaceuticals
• VGXI
• Vical
• Viking Global Investors
• ViroMed
• Vitruvian Networks
• Vor Biopharma
• Washington University
• Weill Cornell Medical College
• Wellcome Trust
• Wellington Capital Management
• WindMIL Therapeutics
• Woodford Investment Management
• Wuhan Union Hospital
• Wuhan Sian Medical Technology
• WuXi AppTec
• X-Body
• Xinqiao Hospital of Chongqing
• Xijing Hospital
• Xuzhou Medical University
• Yale University
• Zelluna Immunotherapy
• Zhejiang Huahai Pharmaceutical
• Zhejiang University
• Zhujiang Hospital
• ZIOPHARM Oncology

For more information about this report visit https://www.researchandmarkets.com/research/3kddhk/tcell?w=12

                    
                    
                    CONTACT: ResearchAndMarkets.com
                             Laura Wood, Senior Manager
                             press@researchandmarkets.com
                             For E.S.T Office Hours Call 1-917-300-0470
                             For U.S./CAN Toll Free Call 1-800-526-8630
                             For GMT Office Hours Call +353-1-416-8900
                             Related Topics: Oncology Drugs